

IBT – International Biotechnology Trust

615.00p ↑ 21.00 +3.54%

EMS: 750

Market Cap
Enterprise Value
Revenue
Position in Market

£242.86m
£288.00m
-£35.24m
- / 1,798

Quality
Value
Momentum

StockRank™

Financials · Conservative · Small Cap · n/a



Momentum

Relative Strength (%)	
1m	-11.7%
3m	-5.70%
6m	-20.4%
1y	-17.9%
Volume Change (%)	
10d / 3m	-4.85%
Price vs... (%)	
52w High	-23.2%
50d MA	-6.65%
200d MA	-14.0%

Growth & Value

Trailing 12m		Industry	Market
PE Ratio (ttm)	n/a		
PEG Ratio (ttm)	n/a		
EPS Growth (ttm)	n/a		
Dividend Yield (ttm)	2.64%		
Valuation (ttm)		Industry	Market
Price to Book Value	0.91		
Price to Tang. Book	0.91		
Price to Free Cashflow	n/a		
Price to Sales	-6.89		
EV to EBITDA	n/a		

Shareholder Activity

	Buy / Hold / Sell
Institutions	<div style="width: 100%; height: 10px; background-color: #ccc;"></div>
Directors	<div style="width: 100%; height: 10px; background-color: #ccc;"></div>
Community	<div style="width: 100%; height: 10px; background-color: #ccc;"></div>

Guru Screens

International Biotechnology Trust didn't qualify for any screens.

Quality

	Industry	Market
Return on Capital	-14.8%	
Return on Equity	-13.6%	
Operating Margin	112.38%	

Financial Summary

Year End 31st Aug		2016	2017	2018	2019	2020	2021	TTM	2022E	2023E	CAGR / Avg
Total Revenue	£m	-3.38	49.0	23.0	-13.8	57.0	32.1	-35.2	1.05		
Operating Profit	£m	-7.11	45.3	20.0	-17.4	53.6	28.0	-39.6			
Net Profit	£m	-7.21	45.3	20.0	-17.5	53.4	27.9	-39.8	-40.9		
EPS Reported	p	-18.5	121	53.2	-46.3	139	68.9	-96.5			
EPS Normalised	p	-18.5	121	53.2	-46.3	139	68.9	-96.5	-63.5	0.000	
EPS Growth	%			-55.9				-50.4			
PE Ratio	x						8.63				
PEG											

Profitability

Operating Margin	%	210	92.4	86.9	127	94.0	87.4	112			116%
ROA	%		18.0	7.45	-6.96	19.7	8.57	-12.4			
ROCE	%	-3.28	17.9	7.62	-7.28	18.9	8.66	-14.8			7.09%
ROE	%		19.3	7.75	-6.99	20.4	9.18	-13.6			9.93%

Cashflow

Op. Cashflow ps	p	55.1	39.2	43.1	17.1	-24.8	-35.9	-64.8			
Capex ps	p	0.000	0.000	0.000	0.000	0.000	0.000	0.000			
Free Cashflow ps	p	55.1	39.2	43.1	17.1	-24.8	-35.9	-64.8			


Dividends

		Ex-date: 30 Dec / Paid: 28 Jan									
Dividend ps	p	11.5	25.0	27.5	26.4	26.6	29.9	15.7	31.3	0.000	21.1%
Dividend Growth	%		+117	+10.0	-4.00	+0.758	+12.4	-44.7	+4.68		
Dividend Yield	%						5.03	2.64	5.27	0.000	
Dividend Cover	x	-1.61	4.82	1.93	-1.76	5.22	2.30	-6.15	-2.03		

Balance Sheet

Cash etc	£m	0.090	0.128	0.142	0.886	0.324	1.56	0.000			76.9%
----------	----	-------	-------	-------	-------	-------	------	-------	--	--	-------

Health Trend (F-Score)



Bankruptcy Risk (Z2-Score)



Earnings Manipulation Risk (M-Score)

Low

Other Ratios

Leverage (ttm)	Total	- Intang	+ Pension
Gross Gearing %	16.9	16.9	16.9
Net Gearing %	16.90	16.90	16.9
Cash / Assets %	0.00		0.0

Liquidity (ttm)

Curr. Ratio	0.00
Quick Ratio	0.00
Interest Cov.	n/a

Efficiency (ttm)

Asset Turnover	-0.11
Recs Turnover	-13.04
Stock Turnover	n/a


Working Capital	£m	-5.14	-16.7	-0.552	2.22	-18.3	-21.6	-45.3		
Net Debt	£m	11.7	6.26	0.232	-0.886	17.8	20.3	45.1		
Net Fixed Assets	£m	222	269	263	237	302	345	312	9.26%	
Book Value	£m	217	253	262	240	284	324	267	8.37%	
Average Shares	m	39	38	38	38	38	40	40	1%	
Book Value ps	p	575	673	699	624	739	782	649	6.35%	

FINANCIAL BRIEF: For the six months ended 28 February 2022, International Biotechnology Trust Plc revenues decreased from... [See more](#)

Recent History

Latest interim period vs. prior period	Industry	Market
Sales Growth	n/a	
EPS Growth	n/a	
3yr Compound Annual Growth Rate	Industry	Market
Sales CAGR	11.71%	
EPS CAGR	9.01%	
DPS CAGR	2.83%	

Graphical History



Analyst Forecasts


Price Target: (0.00% below Price)	31st Aug 2022			31st Aug 2023		
	Net Profit (£)	EPS (p)	DPS (p)	Net Profit (£)	EPS (p)	DPS (p)
Est. Long Term Growth Rate:						
Consensus Estimate	-40.86m	-63.5	31.3			
1m Change	-5.00m	0.0	0.0			
3m Change	-5.00m	0.0	0.0			

Analyst Consensus

0 brokers



EPS 2022 /



Profile Summary

International Biotechnology Trust plc is an investment trust company. The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio o... [Read more](#)

Last Annual	Aug 31, 2021
Last Interim	Feb 28, 2022
Incorporated	Jan 31, 1994
Public Since	Feb 22, 1996
Ex-Dividend Date	Dec 30, 2021
Payment Date	Jan 28, 2022
No. of Employees	n/a
No. of Shareholders	0


Sector	
Industry	
Index	
Exchange	
Asset Category	
Shares in Issue	
Free Float	
Eligible for	

Financials
 Collective Investments
 FTSE All Share Index, FTSE Smallcap Index
 LSE Main Market
 Common Stock
 40,884,909
 37,648,890 (92.09%)
 ✓ ISAs ✓ SIPPs

Address	65 Gresham St, LONDON, EC2V 7NQ, United Kingdom
Web	https://ibtplc.com/
Phone	+442074217070
Contact	Lucy Costa Duarte (Head of Investor Relations)
Auditors	PricewaterhouseCoopers LLP

IBT Share Price Performance

Share Price	Volume	Bid - Ask	Low - High	Spread
615.00p	82,644	615.00p - 620.00p	587.00p - 615.00p	101bps
Day's Change	Avg Volume	Open - Close	Range (12m)	Beta
↑ 21.00 +3.54%	81,900	587.00p - 615.00p	563.00p - 773.25p	0.289



Latest News for IBT

- 10:51 am Announcement
International Biotechnology Trust Plc: Net Asset Value(s)
- Yesterday 9:59 am Announcement
International Biotechnology Trust Plc: Net Asset Value(s)
- Fri, May 13, 2022 Announcement
International Biotechnology Trust Plc: Net Asset Value(s)
- Thu, May 12, 2022 Announcement
International Biotechnology Trust Plc: Net Asset Value(s)
- Wed, May 11, 2022 Announcement
Intnl. Biotechnology - Director/PDMR Shareholding

Upcoming Events for IBT

- Monday, October 31st 2022
Full Year 2022 International Biotechnology Trust PLC Earnings Release

Similar to IBT

Compare

- Aberdeen** abrdn China Investment 92
Contrarian
- BOUSSARD, GAUJARD & FUSTIER** Boussard and Gaujard Holding 85
Neutral
- Blackrock Capital Investment 72
Neutral
- CVC** CVC Credit Partners European Oppo... 84
Super Stock
- ff horizon** Horizon Technology Finance 54
Value Trap
- CQS** CQS New City High Yield Fund 92
Super Stock
- Perpetual Credit Income Trust** 62
Neutral
- ROBECO** Rolinco NV 57
Contrarian

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2022